Filipa Moreira-Silva

Dr. Filipa Moreira-Silva

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
FMFilipa Moreira-Silva
Filipa Moreira-Silva
VCVânia Camilo
Vânia Camilo
Vítor GasparVítor Gaspar
Vítor Gaspar
JMJoão Mano
João Mano
Rui HenriqueRui Henrique
Rui Henrique
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
Epigenetic alterations, as a cancer hallmark, are associated with cancer initiation, progression and aggressiveness. Considering, however, that these alterations are reversible, drugs that target epigenetic machinery may have an inhibitory effect upon cancer treatment. The traditional drug discovery pathway is time-consuming and expensive, and thus, new and more effective strategies are required. Drug Repurposing (DR) comprises the discovery of a new medical indication for a drug that is approved for another indication, which has been recalled, that was not accepted or failed to prove efficacy. DR presents several advantages, mainly reduced resources, absence of the initial target discovery process and the reduced time necessary for the drug to be commercially available. There are numerous old drugs that are under study as repurposed epigenetic inhibitors which have demonstrated promising results in in vitro tumor models. Herein, we summarize the DR process and explore several repurposed drugs with different epigenetic targets that constitute promising candidates for cancer treatment, highlighting their mechanisms of action.

13 July 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MPMariana Brütt Pacheco
Mariana Brütt Pacheco
VCVânia Camilo
Vânia Camilo
NLNair Lopes
Nair Lopes
FMFilipa Moreira-Silva
Filipa Moreira-Silva
MCMargareta Correia
Margareta Correia
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
Among the well-established alterations contributing to prostate cancer (PCa) pathogenesis, epigenetics is an important player in its development and aggressive disease state. Moreover, since no curative therapies are available for advanced stage disease, there is an urgent need for novel therapeutic strategies targeting this subset of patients. Thus, we aimed to evaluate the combined antineoplastic effects of DNA methylation inhibitor hydralazine and histone deacetylase inhibitors panobinostat and valproic acid in several prostate cell lines. The effect of these drugs was assessed in four PCa (LNCaP, 22Rv1, DU145 and PC-3) cell lines, as well as in non-malignant epithelial (RWPE-1) and stromal (WPMY-1) cell lines, using several assays to evaluate cell viability, apoptosis, proliferation, DNA damage and clonogenic potential. We found that exposure to each epidrug separately reduced viability of all PCa cells in a dose-dependent manner and that combined treatments led to synergic growth inhibitory effects, impacting also on colony formation, invasion, apoptotic and proliferation rates. Interestingly, antitumoral effects of combined treatment were particularly expressive in DU145 cells. We concluded that hydralazine and panobinostat attenuate malignant properties of PCa cells, constituting a potential therapeutic tool to counteract PCa progression.

25 April 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
FMFilipa Moreira-Silva
Filipa Moreira-Silva
GOGonçalo Outeiro-Pinho
Gonçalo Outeiro-Pinho
João LoboJoão Lobo
João Lobo
RGRita Guimarães
Rita Guimarães
Vítor GasparVítor Gaspar
Vítor Gaspar
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
Castration-resistant prostate cancer (CRPC) is an incurable form of prostate cancer (PCa), with DNMT1 and G9a being reported as overexpressed, rendering them highly attractive targets for precision medicine. CM-272 is a dual inhibitor of both methyltransferases' activity. Herein, we assessed the response of different PCa cell lines to CM-272, in both 2D and 3D models, and explored the molecular mechanisms underlying CM-272 inhibitory effects. CRPC tissues displayed significantly higher DNMT1, G9a and H3K9me2 expression than localized PCa. In vitro, CM-272 caused a significant decrease in PCa cell viability and proliferation alongside with increased apoptotic levels. We disclose that, under the evaluated dose, CM-272 led to G9a activity inhibition, while not significantly affecting DNMT1 activity. Upon G9a knockdown, DU145 and PC3 showed decreased cell viability. Remarkably, DU145 cells treated with CM-272 or with G9a knockdown displayed no differences in viability, suggesting a SET-dependent mechanism. Contrarily, PC3 cell viability impact was higher in G9a knockdown, compared with CM-272 treatment, suggesting an additional G9a function. Moreover, DU145 cells overexpressing catalytically functional G9a disclosed higher resistance to CM-272 treatment, reinforcing that the drug mechanism of action is dependent on G9a catalytic function. Importantly, we successfully assembled spheroids from several prostate cell lines. Our results showed that CM-272 retained its anti-tumoral effects in 3D PCa models, leading to a clear reduction in cancer cell survival. We concluded that inhibition of G9a methyltransferase activity by CM-272 has anti-tumor effect in PCa cells, holding therapeutic potential against CRPC.

14 October 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
VCVânia Camilo
Vânia Camilo
MPMariana Brütt Pacheco
Mariana Brütt Pacheco
FMFilipa Moreira-Silva
Filipa Moreira-Silva
GOGonçalo Outeiro-Pinho
Gonçalo Outeiro-Pinho
Vítor GasparVítor Gaspar
Vítor Gaspar
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
The androgens/androgen receptor (AR) axis is the main therapeutic target in prostate cancer (PCa). However, while initially responsive, a subset of tumors loses AR expression through mechanisms putatively associated with epigenetic modifications. In this study, we assessed the link between the presence of CpG methylation in the 5′UTR and promoter regions of AR and loss of AR expression. Hence, we characterized and compared the methylation signature at CpG resolution of these regulatory regions in vitro, both at basal levels and following treatment with 5-aza-2-deoxycytidine (DAC) alone, or in combination with Trichostatin A (TSA). Our results showed heterogeneity in the methylation signature of AR negative cell lines and pinpointed the proximal promoter region as the most consistently methylated site in DU-145. Furthermore, this region was extremely resistant to the demethylating effects of DAC and was only significantly demethylated upon concomitant treatment with TSA. Nevertheless, no AR re-expression was detected at the mRNA or protein level. Importantly, after treatment, there was a significant increase in repressive histone marks at AR region 1 in DU-145 cells. Altogether, our data indicate that AR region 1 genomic availability is crucial for AR expression and that the inhibition of histone methyltransferases might hold promise for AR re-expression.

20 September 2026 in Research Square
Verified
Preprint
Open access
PDF file
MJMarianna Kruithof-de Julio
Marianna Kruithof-de Julio
FMFilipa Moreira-Silva
Filipa Moreira-Silva
CMCatarina Macedo-Silva
Catarina Macedo-Silva
MZMarc Zimmerli
Marc Zimmerli
IKIrena Klima
Irena Klima
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
Chromatin accessibility has been shown to stratify prostate cancer (PCa) into clinically relevant subtypes. Chromatin-modifying enzymes, such as histone methyltransferases, modulate nucleosome compactness, and specifically, G9a was found to be overexpressed in PCa. G9a inhibition with CM‑272 demonstrated potent anti-tumor effects, including in PCa in vitro models, although its transcriptomic consequences remain largely unexplored. Here, we used the BM18 PCa patient‑derived xenograft (PDX) model to validate the therapeutic efficacy of CM‑272 and to understand the underlying molecular mechanisms. In vivo G9a inhibition reprogrammed androgen receptor (AR) chromatin distribution in an exposure-time-dependent manner. Short-term treatment displaced AR from key oncogenic loci, associating with reduced expression. Conversely, prolonged exposure decreased H3K9me2 while enhancing AR binding to the promoter of tumor suppressor genes, thereby associating with increased expression. Integration with a published PCa chromatin dataset revealed increased AR scores, suggesting a potential androgen-responsive state. This reprogramming enabled CM‑272 to synergize with enzalutamide in vitro . Moreover, TRAIL pathway enrichment and cell cycle arrest were observed upon short-term treatment, thus sensitizing BM18 organoids to TRAIL‑mediated apoptosis. Collectively, these findings identify G9a as a therapeutically actionable regulator in high-risk, AR-dependent PCa and revealed context-dependent vulnerabilities that may be exploited to delay progression to castration-resistant disease.